F
Filterlex Medical
Filterlex created the CAPTIS® intra-aortic EPD to deflect, capture, and remove embolic particles during TAVI. This new EPD offers full-body protection by trapping and eliminating embolic debris
About Filterlex Medical
Developer of an embolic protection device designed to help patients with complications during catheter-based structural heart procedures. The company's device uses next-generation technology to meet the need of current product limitations and weaknesses and is securely positioned in the aorta to provide full-body embolic protection by deflecting, capturing, and removing embolic particles, enabling physicians to reduce the risk of stroke and other complications during catheter-based structural heart procedures.
Source: Dealroom company dataAt a glance
- Founded
- 2015
- Headquarters
- Yokneam Ilit, Israel
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Parnasa VC
Alon Medtech Ventures
European Innovation Council
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Filterlex Medical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Filterlex Medical on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.